Hinova Pharmaceuticals

Hinova Pharmaceuticals, based in Chengdu, China, is a biotechnology company listed as 688302.SH. Hinova (also known as Haichuang Pharmaceutical) develops innovative drugs in oncology, metabolic disease and autoimmune/inflammatory conditions, using targeted protein degradation, deuterated-drug and translational medicine platforms. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing HP518 - Dose Escalation, HP518 -Dose Expansion and HC-1119 in prostate cancer. The largest, NCT03851640 (A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)), plans to enrol 417 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.